Lonza and Emerald Health enter an agreement for the large-scale manufacturing of a synthetic derivative of CBD and its oral drug product for the treatment of MS and other CNS diseases.
As 3D printing technology continues to develop, it is becoming more disruptive to the pharmaceutical manufacturing industry as its value in drug delivery becomes apparent, according to IDTechEx.
The approval of the farm bill has intensified interest in CBD but Nexien BioPharma CEO warns pharma-grade products are needed for patients with serious conditions.
Purdue announced that it has entered into a partnership deal with Alivio to develop a non-opioid painkiller for the treatment of cystitis and bladder pain syndrome.
SPI Pharma has launched Mannogem XL mannitol for the production of various forms of tablets, which the firm says enhances productivity compared to compendial mannitol.
Nanoform specialises in producing APIs in a nanoparticle size range, which the company claims can significantly improve bioavailability and potentially change the fate of an asset in the clinic.
Ahead of the CPhI Worldwide in Madrid next week, Nemaura announced that it would be showcasing its newly developed 48-hour diclofenac transdermal patch and would be linking up with an unnamed global pharma company to develop three new products.
Insmed has become the first company to receive approval through the limited population pathway for antibacterial and antifungal drugs set up by the US FDA in 2016.
As previously reported, researchers have determined that ketamine has potential as a treatment for patients at imminent risk for suicide, and as a therapy for treatment-resistant depression.
Impel Neuropharma announced the first participant have been dosed in a Phase I trial looking at safety and tolerability for the company’s intranasal olanzapine product.
Researchers from the Clinic for Special Children have developed a drug delivery catheter system that could reach a larger population of patients receive Biogen’s Spinraza treatment.
